BiotechBroyalty aggregator XOMA reports Q3 net income of $14.1 mln

Xoma Royalty

12/11/2025 12:41

Corrects typo in headline

Overview

XOMA reports Q3 net income of $14.1 mln, reversing last year's net loss

Company received $14.3 mln in royalties during Q3, totaling $43.9 mln year-to-date

Outlook

Company anticipates several clinical readouts that could impact business trajectory

Company did not provide specific financial guidance for future quarters

Result Drivers

ROYALTY INTERESTS - Secured royalty interests in partnered assets through acquisition of LAVA Therapeutics

R&D expenses for the three and nine months ended September 30, 2025, were $69 thousand and $1.4 million, respectively, compared with $0.8 million and $2.0 million for each of the corresponding periods of 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
$0.70
Q3 Net Income
$14.10 mln
Q3 Operating Expenses
$10.68 mln
Q3 Operating Income
-$1.33 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the entertainment production peer group is "buy"

Wall Street's median 12-month price target for Xoma Royalty Corp is $55.00, about 37.3% above its November 11 closing price of $34.49

Press Release: ID:nGNX2w5y2D

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)